Viagenpumatucel-L

N/A

Report date: 2024/07/30 13:55:57

Base Information

Drug NameViagenpumatucel-L

Drug Alias Namegp96-Ig lung cancer vaccine - Heat Biologics/University of MiamiGp96-Ig and HLA A1 transfected Non-Small Cell Lung Cancer cell lineAd100-gp96Ig-HLA A1Ad100-gp96Ig-HLA-A1HS-110 +[6]

ClassificationVaccines > Application > Therapeutic vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungLung Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Miami

China Registration ClassN/A

Develop Information

Active CompaniesHeat Biologics

Inactive CompaniesUniversity Of Miami

Active IndicationsCarcinoma, Non-Small-Cell Lung

Inactive IndicationsLung Neoplasms

Other Information

ATC CodeN/A